Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
The Mitra-FR study, which found that Abbott’s MitraClip failed to improve patients’ health, has been contradicted spectacularly by Coapt. So which one is right?
The industry leader’s biggest buy since Covidien gets it into robots, but direct competition with Intuitive is unlikely.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
Apple has obtained its first FDA clearance, putting the Apple Watch on the same footing as Alivecor’s KardiaBand – but the smaller group is fighting back.
Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
Since becoming a pure-play health tech group Philips has been buying like crazy. Might Siemens Healthineers and GE Healthcare join in?